- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01668732
Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts
Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task.
It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning.
Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Sheng Chang Wang, M.D., M.Sc.
- Phone Number: 36703 886-37-246166
- Email: scwang69@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
community heroin addicts
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sheng Chang Wang, M.D., M.Sc., National Health Research Institute, Taiwan
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD101SCW01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heroin Addiction
-
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio...Solaris CROCompleted
-
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio...Completed
-
Psychiatric University Hospital, ZurichUnknownHeroin AddictionSwitzerland
-
Tang-Du HospitalUnknownRelapse | Heroin AddictionChina
-
Region SkaneSwedish Council for Working Life and Social ResearchCompletedSubstance Use Disorders | Heroin AddictionSweden
-
Shanghai Mental Health CenterShanghai Center of Biomedicine DevelopmentCompleted
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
National Health Research Institutes, TaiwanUnknown
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Substance Withdrawal SyndromeUnited States